Fulltext

Nutraceuticals and mitochondrial oxidative stress: bridging the gap in the management of bronchial asthma

Allam VSRR 1 , Paudel KR 2 , Gupta G 3 , Singh SK 4 , Vishwas S 4 , Gulati M 4 Show all authors , Gupta S 5 , Chaitanya MVNL 5 , Jha NK 6 , Gupta PK 7 , Patel VK 8 , Liu G 2 , Kamal MA 9 , Hansbro PM 2 , Oliver BGG 10 , Chellappan DK 11 , Dua K 12

Affiliations 

  • 1 Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
  • 2 Centre for Inflammation, Centenary Institute and University of Technology Sydney, School of Life Sciences, Faculty of Science, Sydney, NSW, 2007, Australia
  • 3 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, India
  • 4 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
  • 5 Chitkara College of Pharmacy, Chitkara University, Punjab, India
  • 6 Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, Uttar Pradesh, India
  • 7 Department of Life Sciences, School of Basic Sciences and Research (SBSR), Sharda University, Greater Noida, Uttar Pradesh, Australia
  • 8 School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, 2052, Australia
  • 9 King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah, 21589, Saudi Arabia
  • 10 School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, Australia
  • 11 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia
  • 12 Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia. kamalpharmacist02@gmail.com
Environ Sci Pollut Res Int, 2022 Sep;29(42):62733-62754.
PMID: 35796922 DOI: 10.1007/s11356-022-21454-w

Abstract

Asthma is a chronic inflammatory disease primarily characterized by inflammation and reversible bronchoconstriction. It is currently one of the leading causes of morbidity and mortality in the world. Oxidative stress further complicates the pathology of the disease. The current treatment strategies for asthma mainly involve the use of anti-inflammatory agents and bronchodilators. However, long-term usage of such medications is associated with severe adverse effects and complications. Hence, there is an urgent need to develop newer, novel, and safe treatment modalities for the management of asthma. This has therefore prompted further investigations and detailed research to identify and develop novel therapeutic interventions from potent untapped resources. This review focuses on the significance of oxidative stressors that are primarily derived from both mitochondrial and non-mitochondrial sources in initiating the clinical features of asthma. The review also discusses the biological scavenging system of the body and factors that may lead to its malfunction which could result in altered states. Furthermore, the review provides a detailed insight into the therapeutic role of nutraceuticals as an effective strategy to attenuate the deleterious effects of oxidative stress and may be used in the mitigation of the cardinal features of bronchial asthma.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications